Next Article in Journal
Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome
Next Article in Special Issue
Biocide Use in the Antimicrobial Era: A Review
Previous Article in Journal
Conformation of G-quadruplex Controlled by Click Reaction
Previous Article in Special Issue
Antimicrobial Activity of Gemini Surfactants with Azapolymethylene Spacer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 18
10.3390/molecules25184341
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Bis-Ammonium Salts of Pyridoxine: Synthesis and Antimicrobial Properties

by
Nikita V. Shtyrlin
1,
Mikhail V. Pugachev
1,
Sergey V. Sapozhnikov
1,
Marsel R. Garipov
1,
Rusalia M. Vafina
1,
Denis Y. Grishaev
1,
Roman S. Pavelyev
1,
Renata R. Kazakova
1,
Mariya N. Agafonova
1,
Alfiya G. Iksanova
1,
Svetlana A. Lisovskaya
2,
Marina I. Zeldi
1,
Elena S. Krylova
1,
Elena V. Nikitina
1,
Alina E. Sabirova
1,
Airat R. Kayumov
1 and
Yurii G. Shtyrlin
1,*
1
Kazan (Volga region) Federal University, Scientific and Educational Center of Pharmaceutics, Kremlyovskaya St. 18, Kazan 420008, Russia
2
Kazan Scientific Research Institute of Epidemiology and Microbiology, Kazan 420015, Russia
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(18), 4341; https://doi.org/10.3390/molecules25184341
Submission received: 21 August 2020 / Revised: 14 September 2020 / Accepted: 17 September 2020 / Published: 22 September 2020
(This article belongs to the Special Issue Microbiocides Chemistry)
Browse Figures
Versions Notes

Abstract

:
A series of 108 novel quaternary bis-ammonium pyridoxine derivatives carrying various substituents at the quaternary nitrogen’s and acetal carbon was synthesized. Thirteen compounds exhibited antibacterial and antifungal activity (minimum inhibitory concentration (MIC) 0.25–16 µg/mL) comparable or superior than miramistin, benzalkonium chloride, and chlorhexidine. A strong correlation between the lipophilicity and antibacterial activity was found. The most active compounds had logP values in the range of 1–3, while compounds with logP > 6 and logP < 0 were almost inactive. All active compounds demonstrated cytotoxicity comparable with miramistin and chlorhexidine on HEK-293 cells and were three-fold less toxic when compared to benzalkonium chloride. The antibacterial activity of leading compound 5c12 on biofilm-embedded Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli or Pseudomonas aeruginosa was comparable or even higher than that of the benzalkonium chloride. In vivo 5c12 was considerably less toxic (LD50 1705 mg/kg) than benzalkonium chloride, miramistine, and chlorhexidine at oral administration on CD-1 mice. An aqueous solution of 5c12 (0.2%) was shown to be comparable to reference drugs efficiency on the rat’s skin model. The molecular target of 5c12 seems to be a cellular membrane as other quaternary ammonium salts. The obtained results make the described quaternary bis-ammonium pyridoxine derivatives promising and lead molecules in the development of the new antiseptics with a broad spectrum of antimicrobial activity.

Graphical Abstract

1. Introduction

The drastic worldwide rise of antimicrobial drug resistance would lead to the death of 10 million people every year by 2050, which becomes a proven and challenging problem [1,2]. In comparison with antibiotics for systemic application, antiseptics are characterized by a wider spectrum of antimicrobial action against bacteria, fungi, viruses, and protozoa [3,4]. Therefore, antiseptics are an important integral part of stewardship strategies for preventing and treating the surgical site and chronic open wound infections [5].
QAC (quaternary ammonium compounds) is one of the best-known group of antiseptics. The prominent representatives of this class are benzalkonium chloride, cetylpyridinium chloride, miramistin, and didecyldimethylammonium chloride [6,7]. The mechanism of the antibacterial action of QAC consists of their adsorption and penetration through the cell wall of bacteria, which is followed by an interaction with phospholipids of the cytoplasmic membrane and subsequent complete structural disorganization of the membrane and subsequent cell death [3].
Since QAC-based antiseptics could be inefficient because of acquired resistance [3,8], have high toxicity [9], lead to skin irritation [10], and demonstrate low activity against spores, simple viruses, Gram-negative bacteria, mycobacteria, and fungi [11], the development of new antiseptic molecules is strictly required. Therefore, the goal of this study was developing new drugs that would strengthen all the advantages of QAC and eliminate their disadvantages as well.
In our group, we have systematically studied chemistry and biological properties of the pyridoxine (vitamin B6) derivatives [12]. In previous works, we described a series of QAC based on pyridoxine derivatives [13,14,15,16,17]. Some of them possess high antibacterial activity against various Gram-positive and Gram-negative bacteria including multi-resistant clinical isolates (MICs = 0.5–16 µg/mL) and low toxicity in vitro. In our patents [18,19], we described the synthesis of the bis-ammonium salt 5c12 with advantageous antimicrobial properties (Figure 1). These promising results encouraged us to synthesize and study an extended set of modified structural analogs of 5c12, which bears various substituents at the quaternary nitrogens and acetal carbon.

2. Results and Discussion

In the work [18], we described the first synthesis of compound 5c12 in seven steps with the overall yield of only 13%. Then we developed a new synthetic approach in four steps with an overall yield of 22% [19]. For the synthesis of its analogues 5a8–5r18, we used the same approach with some modifications (Scheme 1). An approach includes the initial preparation of six-membered acetals 2a–r with different substituents at acetal carbon [20,21]. At the second stage, in reaction of 2a–r with thionyl chloride in chloroform led to the corresponding chlorides 3a–r with quantitative yields. Then, via chlorination of aromatic methyl group with trichloroisocyanuric acid (TCICA) in chloroform dichloro derivatives 4a–r were obtained. The use of other chlorinating agents (N-chlorosuccinimide, sulfuryl chloride), varying solvents (methylene chloride, tetrachloroethane), and radical reactions initiators (AIBN, ACHN, benzoyl peroxide) did not lead to desired products. At the last stage, in reaction of dichlorides 4a–r with a two-fold molar excess of tertiary amines (N,N-dimethyoctylamine, N,N-dimethyldecylamine, N,N-dimethyldodecylamine, N,N-dimethyltetradecylamine, N,N-dimethylhexadecylamine, N,N-dimethyloctadecylamine) in ethanol at 70 °C 108 bis-ammonium compounds 5a8–5r18 were obtained. The substituent’s variations allowed varying compound’s lipophilicity and, thus, investigate the lipophilicity-activity relationships.

2.1. Antibacterial Activity

The antibacterial activity of 108 newly synthesized compounds was evaluated against three Gram-positive and three Gram-negative bacterial strains. Table 1 shows MICs of compounds in comparison with miramistin, benzalkonium chloride, and chlorhexidine. The lipophilicity of the synthesized ammonium salts was expressed in terms of their partition coefficient values (logP) calculated using online platform Chemicalize (ChemAxon) [20].
All compounds with tetradecyl, hexadecyl, and octadecyl substituents at the quaternary nitrogens were almost inactive regardless of the substituent on the acetal carbon atom. For compounds with small substituents at acetal carbon (H, CH3, C2H5, C3H7, CH(CH3)2) against all bacterial strains, the most active were compounds with decyl substituents at quaternary nitrogens (5a10, 5b10, 5c10, 5d10, 5e10, MICs 0.5–8 µg/mL on Gram-positive and 2–64 µg/mL on Gram-negative strains). Compounds with dodecyl substituents were slightly less active (5a12, 5b12, 5c12, 5d12, and 5e12) and compounds with octyl substituents (5a8, 5b8, 5c8, 5d8, and 5e8) were inactive.
Due to an increase of the length of substituents on acetal carbon (C4H9, C(CH3)3, CH(CH3)C2H5, C5H11, and CH(C2H5)C2H5, C6H13), the most active were compounds with decyl substituents at quaternary nitrogens (5f10, 5g10, 5h10, 5i10, 5j10, 5k10, 5l10, MICs 0.25–4 µg/mL on Gram-positive and 0.5–8 µg/mL on Gram-negative strains). Compounds with octyl and dodecyl substituents had similar activity and were less active than compounds with decyl substituents. A similar activity pattern was observed for compounds with a cyclohexyl substitutent at acetal carbon (5r8–5r12).
With the further increase in the length of the substituents at the acetal carbon (C7H15, CH(C2H5)C4H9, C8H17, CH(CH3)C9H19), compounds with octyl substituents at quaternary nitrogens (5m8, 5n8, 5o8, 5p8, 5q8) became the most active (MICs 0.5–2 µg/mL on Gram-positive and 1–16 µg/mL on Gram-negative strains). Compounds with decyl substituents were slightly less active (5m10, 5n10, 5o10, 5p10, and 5q10) and compounds with dodecyl substituents were almost inactive.
Based on the results of the primary screening, 13 compounds (5a12, 5c10, 5c12, 5d10, 5f10, 5g10, 5i10, 5l10, 5m8, 5n10, 5o8, 5p8, and 5q8 in bold in Table 1) with an activity similar or superior when compared reference drugs were selected for further in-depth investigation for antibacterial activity, antifungal activity, and cytotoxicity in vitro.
The results of investigation of antibacterial activity on clinical Gram-positive and Gram-negative bacterial isolates is presented in Table 2. The most active were 5c12, 5i10, 5l10, 5n10, 5o8, 5p8, and 5q8, whose activity significantly exceeded that of all reference drugs. Compounds 5a12, 5f10, 5g10, and 5m8 exhibited, in general, antibacterial activity comparable to that of benzalkonium chloride and significantly exceeded miramistin and chlorhexidine in activity. Compounds 5c10 and 5d10 were almost inactive on all strains besides S. aureus 25 and S. intermedius 1143 MRSI (methicillin-resistant Staphylococcus intermedius).

2.2. Structure-Activity Relationship (SAR)

To identify quantitative relationships “structure–antibacterial activity” in a series of synthesized QACs based on vitamin B6 derivatives 5a8–5r18, the dependences of antibacterial activity on calculated in ChemAxon lipophilicity [22] were evaluated (Figure 2, for S. epidermidis and K. pneumoniae 1813). A strong correlation between the lipophilicity and antimicrobial activity of quaternary ammonium pyridoxine derivatives on S. epidermidis and K. pneumonia was observed. Thus, all the most active compounds had logP values in the range of 1–3, while compounds with logP > 6 and logP < 0 were almost inactive. Similar relationships were found for the other studied bacteria. Apparently, relationships reflect the important features of the active compounds essential for their effective interaction with the hydrophobic membrane core of bacterial cells.

2.3. Antifungal Activity

The antifungal activity is an important characteristic of antiseptics. Therefore, the effect of 5a12, 5c10, 5c12, 5d10, 5f10, 5g10, 5i10, 5l10, 5m8, 5n10, 5o8, 5p8, and 5q8 on growth of various fungal pathogens has been evaluated (Table 3).
Compound 5c10, 5c12, 5d10, 5f10, 5n10, and 5p8 exhibited a pronounced antifungal activity against all tested fungi with minimum inhibitory concentrations (MIC) lower than all reference drugs. The highest activity demonstrated compound 5d10 with MIC values of 2–4 µg/mL against all tested fungi. Compounds 5a12, 5g10, 5i10, 5l10, 5o8, and 5q8 had a comparable activity with miramistin. Compound 5m8 was almost inactive on all tested fungi similar to chlorhexidine.

2.4. Cytotoxicity

Cytotoxicity of compounds 5a12, 5c10, 5c12, 5d10, 5f10, 5g10, 5i10, 5l10, 5m8, 5n10, 5o8, 5p8, and 5q8 was evaluated on HEK-293 cells (Table 4). According to the results obtained, all compounds had values of cytotoxicity comparable with miramistin and chlorhexidine and were 2–4-fold less toxic when compared to benzalkonium chloride.

2.5. In Vivo Toxicity

For the lead antibacterial and antifungal compounds 5c12, 5d10, and 5p8 in vivo toxicity at oral administration on CD-1 mice were performed as described in Section 3.5 (Table 5). No remarkable findings were noted in both sexes in compound 5c12 treatment group at necropsy. Compounds 5d10 and 5p8 treatment groups revealed stomach walls hypertrophy. Thus, all studied substances belong to category 4 of the globally harmonized system of classification and labeling of chemicals [23]. Compound 5c12 was considerably less toxic (LD50 1705 mg/kg) than benzalkonium chloride (LD50 180 mg/kg [24]), miramistine (LD50 1000 mg/kg [25]), and chlorhexidine (LD50 1260 mg/kg) [26]). Compounds 5d10 and 5p8 are 2-fold and 4-fold more toxic when compared to 5c12.
Thus, the extensive screening of the antibacterial activity and toxicity of the modified structural analogs of compound 5c12 did not reveal compounds superior in antibacterial activity. In addition, its in vivo toxicity was significantly lower than that of compounds with comparable activity. For this reason, 5c12 was selected as a lead compound for further investigations.

2.6. Anti-Biofilm Activity

The anti-biofilm activity of 5c12 has been tested on biofilms formed by S. aureus, S. epidermidis, E. coli, or P. aeruginosa. For that, 48-h-old bacterial biofilms prepared in 24-well plates were washed with sterile phosphate-buffered saline (PBS) and filled with 125 μL of fresh basal medium (BM) broth containing 5c12, miramistin, or benzalkonium chloride in concentrations of their respective 8–16 × MBC (minimum bactericidal concentration, see Table 6 for values). After 24 h of incubation, the viability of biofilm-embedded cells was evaluated by colony-forming units (CFUs) counting.
In these experiments, 5c12 exhibited higher activity compared with the reference antimicrobials: a 3-log drop of CFUs of these bacteria was observed at 2 × MBC of 5c12 (Figure 3), while 8 × MBCs of both benzalkonium chloride and miramistin were required to obtain the same effect. Moreover, both reference antimicrobials were less active against P. aeruginosa biofilm even at 16 × MBC, while 5c12 reduced the CFUs number by three orders of magnitude at 8 × MBC (Figure 3D). Thus, 5c12 demonstrated anti-biofilm activity comparable or even higher than that of the benzalkonium chloride.

2.7. In Vivo Efficiency

In vivo efficiency of 5c12 was estimated in a rat skin model in comparison with miramistin, benzalkonium chloride and chlorhexidine. Aqueous solution of 0.2% 5c12 reduced CFU (colony-forming unit) of E. coli CD CF-50 after 5 min of exposure on rat’s skin (Table 7).
Compound 5c12 demonstrated the strongest E. coli CD CF-50 growth inhibition (Figure 4). The growth inhibition percentage reached 97.5%, which is comparable to reference drugs’ efficiency [27].

2.8. Cytoplasmic Membrane Depolarization

Quaternary ammonium salts are well known for their membrane-damaging action on bacterial cells [28]. To evaluate the effect of 5c12 on the membrane polarization, the fluorescence of membrane-potential-sensitive cyanine dye DiSC3(5) in suspensions of either S. aureus ATCC209p or E. coli CDCF-50 has been measured in the presence of 5c12 or either benzalkonium chloride or miramistin (Figure 5). In the presence of 5c12 and reference compounds, a rapid and intense increase of fluorescence of DiSC3(5) has been observed in both S. aureus and E. coli suspensions. It was shown that the ability of 5c12 to change the electric potential of the bacterial membrane was comparable to the reference compounds. Significant differences between untreated cells and treated by 5c12 (p ≤ 0.05) cells were observed after 20 min of incubation (Figure 5C,D). When the 5c12 concentration increased from 1 × MBC to 2, 4, and 8 × MBC, the membrane-damaging effect has been achieved two times faster. We found that a 10-min incubation of cells with 5c12 led to significant differences in the control (Figure 5A,B).

2.9. Outer Membrane Permeability

Since the membrane depolarization can be driven with either membrane permeabilization or a metabolism drop, the ability of 5c12 to permeate the bacterial outer membrane was determined using the fluorescent dye N-phenyl-1-naphthylamine (NPN). A strong dose-dependent response of 5c12 on the Gram-negative bacteria outer membrane penetration was observed. For untreated E. coli cells, the permeability was 45%. In the presence of 1 × MBC of 5c12, the outer membrane permeability increased to 70% with increasing concentrations (2 × and 4 × MBC) of 5c12. The membrane permeability reached more than 80%.

2.10. Scanning Electron Microscopy

The data presented above allow suggesting the destabilizing effect of 5c12 on the bacterial membrane, which leads to an antiseptic effect of the drug. These assumptions are confirmed by the SEM images of treated cells (Figure 6).
Thus, while the untreated S. aureus cells had a spherical regular shape with a dense surface with small gentle tubercles without vortices, dead cells were not detected in the visual fields (Figure 6A). After 5c12 treatment, dead cells with a shrunken cell membrane were observed. The shape of most cells became non-spherical and irregular with a losing surface and organic matter on most of the cells, possibly due to damage of the cytoplasmic membrane and leakage of internal contents (Figure 6C). A number of cells exhibited deep creases, which indicated the folding of the cell wall into the cell due to the outflow of cytoplasm. In contrast to S. aureus, untreated E. coli cells had a wrinkled surface (Figure 6B). After 5c12 treatment, the cell surface became more spongier due to this, which indicated the change in the structure of the cell wall (Figure 6D).

3. Materials and Methods

3.1. Chemistry

All reagents were obtained from commercial sources and were used without further purification unless otherwise stated. 1H and 13C NMR spectra were recorded on a ‘Bruker AVANCE 400′ at an operating frequency of 400 and 101.56 MHz, respectively. Chemical shifts were measured with reference to the residual protons of the solvent (CDCl3, 1H, 7.26 ppm, 13C, 77.16 ppm, DMSO-d6, 1H, 2.50 ppm, 13C, 39.51 ppm). Coupling constants (J) are given in Hertz (Hz). The following abbreviations are used to describe coupling: s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet, br m = broad multiplet, AB = AB system. Melting points were determined using a Stanford Research Systems MPA-100 OptiMelt melting point apparatus and are uncorrected. For TLC (thin-layer chromatography) analysis, silica gel plates from Sorbfil (Krasnodar, Russia) were used with UV light (254 nm/365 nm) or iron (III) chloride as a developing agent. Column chromatography was performed on silica gel (60–200 mesh) from Acros.
HRMS (high-resolution mass spectrometry) spectra were obtained on a quadrupole time-of-flight (t, qTOF) AB Sciex Triple TOF 5600 mass spectrometer using a turbo-ion spray source (nebulizer gas nitrogen, a positive ionization polarity, needle voltage 5500V). Recording of the spectra was performed in the “TOF MS” mode with collision energy 10 eV, declustering potential of 100 eV, and a resolution of more than 30,000 full-width half-maximum. Samples with the analyte concentration of 5 μmol/L were prepared by dissolving the test compounds in a mixture of methanol (HPLC-UV Grade, LabScan) and water (LC-MS Grade, Panreac) in a 1:1 ratio.
Methods of synthesis and analytical characteristics of all new synthesized compounds are described in the Electronic Supplementary Material.

3.2. Antibacterial Activity

The antibacterial activity of the obtained compounds was evaluated on a number of Gram-positive bacteria: Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis (clinical isolate), Bacillus subtilis 168, and Gram-negative bacteria: Escherichia coli ATCC 25922, Klebsiella pneumoniae 1813 (clinical isolate), Pseudomonas aeruginosa ATCC 27853. The antibacterial activity of compounds 5a12, 5c10, 5c12, 5d10, 5f10, 5g10, 5i10, 5l10, 5m8, 5n10, 5o8, 5p8, and 5q8 was additionally evaluated on clinical methicillin-resistant strains of Staphylococcus haemolyticus 837 MRSH (methicillin-resistant Staphylococcus haemolyticus), Staphylococcus aureus 967 MRSA (methicillin-resistant Staphylococcus aureus), Staphylococcus aureus 983 MRSA, Staphylococcus aureus 25, Staphylococcus intermedius 1143 MRSI, Staphylococcus aureus 2020 MRSA, Moraxella sp. 764, Moraxella sp. 765, Moraxella sp. 829, Acinetobacter spp. 1, Acinetobacter spp. 3, Pseudomonas spp. 5, Pseudomonas spp. 6, Klebsiella spp. 11, Klebsiella spp. 12, and Proteus spp. 17, which were obtained from patients with bronchopulmonary diseases in the laboratory of bacteriology of the republic clinical hospital (Kazan, Russia).
The minimum inhibitory concentration (MIC) of compounds was determined by the broth microdilution method in 96-well microtiter plates (Eppendorf), according to the EUCAST (European Committee on Antimicrobial Susceptibility Testing) rules for antimicrobial susceptibility testing with some modifications [16]. The bacterial culture adjusted to 3–9 × 106 cells/mL in the Mueller Hinton (MH) broth was seeded into 96-well polystyrol culture plates (Eppendorf). The concentrations of substances to be tested ranged from 0.25 to 64 µg/mL in two-fold serial dilutions. The minimal inhibitory concentration was determined as the lowest concentration of the compound, which leads to no visible bacterial growth after 24 h of incubation. To determine a minimum bactericidal concentration (MBC), a culture liquid from wells without visible growth was diluted one thousand-fold into new 96-well microtiter plates in fresh MH-broth and incubated for 24 h growth at 35 °C. MBC was assumed at concentrations where no viable growth could be observed.

3.3. Antifungal Activity

Antifungal activity of compounds 5a12, 5c10, 5c12, 5d10, 5f10, 5g10, 5i10, 5l10, 5m8, 5n10, 5o8, 5p8, and 5q8 was evaluated on several fungal strains, which causes cutaneous and systemic mycoses. The fungal isolates were obtained from a collection of the Kazan Institute of Microbiology and Epidemiology (Kazan, Russia): Candida albicans NCTC- 885–653 (etalon strain), Aspergillus niger F-1119 (etalon strain), Trichophyton rubrum 1336 (clinical strain), and Fusarium oxysporum KM-19 (clinical strain). For the inoculum preparation, the pure 2-day and 5-day cultures of yeasts and filamentous fungi, respectively, grown on Sabouraud dense nutrient medium, were used. Yeast cultures of C. albicans were prepared by flushing the culture from the surface of the solid agar medium. Cultures of mycelial fungi T. rubrum, F. oxysporum, and A. niger were preground in a mortar. A suspension of microorganisms was prepared in a sterile 0.9% NaCl in pure water. The cell concentrations were (1–5) × 103 for yeast fungi and (1–5) × 104 for mycelial fungi.
The in vitro evaluation of the antifungal activity of compounds was carried out in a liquid glucose Sabouraud broth in biological test tubes by a two-fold serial dilution approach. Test compounds were prepared at concentrations ranging from 400 to 0.38 µg/mL. A test tube in the absence of test compounds served as a control. To each tube, 50 µL of inoculum was added. The tubes were incubated for 2–7 days at 30 °C. To the end of this period, the results were assessed by visual analysis of optical density of the medium. The following MIC endpoints were determined: 0 = clear solution, no growth, 1 = weak growth (25% control), 2 = significant inhibition of growth (50% control), 3 = insignificant growth inhibition (75% control), and 4 = no growth inhibition. All experiments were carried out in duplicate.

3.4. Cytotoxicity

The cytotoxicity was evaluated on HEK 293 (human embryonic kidney) cells by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were cultured in α-MEM (minimum essential medium) supplemented with 10% FBS (fetal bovine serum), 2 mM L-glutamine, 100 μg/mL penicillin, and 100 μg/mL streptomycin. Cells were seeded in 96-well plates at the density of 10,000 cells per well and grown overnight at 37 °C and 5% CO2 in humidified atmosphere. Then the medium was changed to the fresh one containing compounds to be tested in a concentration of 0.1–100 μg/mL. After 72 h of cultivation, the cultural fluid was discarded and the MTT solution (in DPBS (Dulbecco’s phosphate-buffered saline)) was added to the fresh media until reaching a final concentration of 0.5 mg/mL. After 2 h, the liquid was replaced with dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO) to dissolve formazan crystals, and absorption was measured on Tecan Infinite 200Pro at 550 nm with a reference of 700 nm. Based on data obtained, the CC50 values (concentrations decreasing the metabolic activity by two-fold) were calculated.

3.5. Anti-Biofilm Activity

Bacterial biofilms were grown under static conditions in BM broth [29,30] for 48 h at 37 °C, washed, and exposed to 1–16 × MBCs of antimicrobials for 24 h in fresh BM. Then the culture liquid was discarded. The biofilms were washed with sterile 0.9% NaCl and suspended in 0.9% NaCl by scratching the well bottoms with the following treatment in a sonicator bath for 2 min at 20 kHz to favor the disintegration of cell clumps, and viable cells were counted using a drop plate assay [31] with modifications [32,33]. Serial 10-fold dilutions of each well were prepared in sterile 0.9% NaCl and 5 µL of the suspension was dropped onto solid LB (Luria broth) plates. CFUs were counted from those drops containing 5–10 colonies, which were averaged and presented as CFU per cm2.

3.6. Animals

Male and female CD-1 (ICR) mice (weighing 18–22 g) were purchased from the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences. Male Sprague-Dawley rats weighing 200–230 g were purchased from the laboratory animals nursery “Pushchino,” Russia. Animals were given a laboratory rodent diet and water ad libitum. They were housed in polypropylene cages with sawdust at room temperature of 22 ± 3 °C and a relative humidity of 50 ± 20% with a constant 12-h light/dark cycle. All animals acclimatized for two weeks before the experiment. All experimental procedures were performed in accordance with the Ethical Principles in Animal Research and were approved by the Local Ethics Committee №2-2017 of the Kazan Federal University.

3.7. In Vivo Toxicity

Mice were stratified by weight and randomly assigned into one sex group of three per group (for initiating dose). The number of animals in the group was increased to six per group if necessary. Prior to the experiment, animals were weighed, marked, and fasted for 8 h with free access to water. Compounds 5c12, 5d10, and 5p8 were dissolved in distilled water and administered to the mice by oral gavage at doses 50, 100, 500, 1000, 1500, and 2000 mg/kg body weight. The initial dose of 1000 mg/kg was selected as the dose expected to produce mortality in some animals. Further groups of animals have been dosed at higher or lower fixed doses, depending on the presence of mortality, until the study objective was achieved. All animals were observed twice daily for symptoms and mortality for two weeks. All surviving animals were euthanized with CO2 inhalation at the end of the study on day 14, and their vital organs were individually observed for overt pathology by necropsy, and the LD50 was calculated by Probit analysis in IBM SPSS Statistics software.

3.8. In Vivo Efficiency in a Rat Skin Model

Gram-negative (E. coli CDC F-50™) bacteria were used as test organisms for the in vivo rat skin model. The culture of E. coli CDC F-50, grown on Mueller-Hinton’s medium (MHB, NICF, Russia) for 18–20 h, were washed off with sterile isotonic chloride solution, and centrifuged at 5000 rpm for 5 min. The supernatant was discharged and the cells were resuspended with sterile isotonic sodium chloride solution.
Endo medium (HiMedia Laboratories Pvt. Ltd., Mumbai, India) were used according to the manufacturers’ instructions. Phosphate-buffered saline (PBS, Ekoservice, Russia), Tween 80 (Sigma-Aldrich, St Louis, MO, USA), saponin (Dia-M, Moscow, Russia), histidine (Sigma-Aldrich, St Louis, MO, USA), and cysteine (Sigma-Aldrich, St Louis, MO, USA) were used for neutralizing solution (3% v/v Tween 80, 3% w/v saponin, 0.1% w/v histidine, 0.1% w/v cysteine, PBS).
Thirty rats were randomly assigned to five groups: four experimental groups and one control group with six rats in each group. All rats were anesthetized with isoflurane (induction 3.0% in air, maintenance of 1.5% in air) [34]. On the experimental day, dorsal sites of the animals more than 5 × 5 cm were shaved, and squares 5 × 5 cm were outlined with the marker. Suspension (0.25 mL) containing 1 × 107 CFU E. coli CDC F-50 were applied on the selected area, distributed with a sterile disposable spatula over the entire area of the square, and left for 3–4 min until it dries. Then a gauze cloth (5 × 5 cm) was applied to the rat’s skin for 5 min. In experimental groups, gauze cloths were preliminarily wetted in 1 mL of 0.2% 5c12, miramistin, benzalkonium chloride or chlorhexidine solutions. In a negative control group, the tissue was immersed in 1 mL of sterile saline. At the end of the exposure time in experimental groups, the neutralizer was used to stop antiseptic action on bacteria. The rat’s skin was washed with a sterile gauze (5 × 5 cm) moistened with a sterile neutralizer solution. Then, the gauze cloth was transferred into 50-mL tubes with sterile physiological saline (10 mL) and shaken for 10 min. Then the washing liquid was placed into two to three plates (0.1 mL on each plate) in a selective Endo medium, and cultured for 24–48 h at 37 °C.
After the time required for cultivation of microorganisms, the results were recorded by the number of colonies grown on the Petri dish. The results were taken into account by assessing the residual contamination of surfaces after treating them with antiseptic solution. After counting the number of colonies grown on Petri dishes, the density of contamination per 1 cm2 of the surface and the percentage of disinfection were calculated, which corresponds to the number of colonies removed from the control surfaces that were not exposed to antiseptics as 100%. The percentage of growth inhibition of E. coli CDC F-50 was calculated using the following formula:
I = 100 % − E × 100 % C ,   where
I—percentage of growth inhibition, %,
C—the number of colonies in the control group,
E—the number of colonies in the experimental group.

3.9. Outer Membrane Permeability

The outer membrane permeability was assessed by measuring the fluorescent dye NPN (1-N-phenylnaphthylamine) uptake [35,36]. Gram-negative bacteria (E. coli CDCF-50) were incubated to mid-log phase in Mueller Hinton broth (37 °C, 120 rpm), harvested by centrifugation (3.000 rpm for 10 min), washed twice, and diluted to 105 CFU/mL with 5 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid) buffer (pH 7.4, containing 5 mM glucose). Then, 200 μL of suspension were placed into a 96-well plate which were mixed with 10 μM of NPN. The background fluorescence was recorded (excitation λ = 350 nm, emission λ = 420 nm) by Spectrophotometer Infinite M200 PRO (Tecan, Switzerland). Next, 20 μL of 5c12 with final concentrations equal to minimal bactericidal concentration (MBC), 2 × MBC, and 4 × MBC, was added to the E. coli suspension into a 96-well plate. The fluorescence was recorded until no further increase of fluorescence was detected. The NPN uptake percent was calculated using the following formula:
NPN uptake (%) = (Fobs − F0)/(F100 − F0) × 100%, where
Fobs—fluorescence of 5c12 in MBC/2 × MBC/4 × MBC,
F0—the initial NPN fluorescence with E. coli in the absence of 5c12,
F100—NPN fluorescence with E. coli after addition of 10 μg/mL polymyxin B (Sigma-Aldrich, St Louis, MO, USA), which was used as a positive control.

3.10. Cytoplasmic Membrane Depolarization Assays

The cytoplasmic membrane depolarization was determined by using the membrane potential-sensitive fluorescent dye 3,3-Dipropylthiadicarbocyanine Iodide DiSC3(5), (Sigma-Aldrich). Gram-positive (S. aureus ATCC209p) and Gram-negative (E. coli CDCF-50) bacteria were incubated to a mid-log phase in Mueller Hinton broth (37 °C, 120 rpm), harvested by centrifugation (3.000 rpm for 10 min), washed twice, and diluted to an optical density of 0.05 at 600 nm with 5 mM HEPES buffer (pH 7.4, containing 20 mM glucose) containing 0.1 M KCl to equilibrate the cytoplasmic and external K+. Then, the cell suspensions (180 μL) were mixed with 20 μL of 0.8 μM DiSC3(5) in a 96-well plate and incubated for 15 min in darkness (until maximal dye uptake was reached, the background fluorescence was recorded (excitation λ = 620 nm, emission λ = 670 nm) by Spectrophotometer Infinite M200 PRO (Tecan, Switzerland). After that, 5c12 and reference compounds (benzalkonium chloride, miramistin) in 0.5, 1, and 2 × MBCs were added to cell suspensions into a 96-well plate. Changes in fluorescence were observed during 20 min of recording.

3.11. Scanning Electron Microscopy

The analysis was carried out using a high-resolution scanning electron microscope Merlin (Carl Zeiss, oberkochen, Germany). The surface morphology was studied at an accelerating voltage of primary electrons of 5 kV and a probe current of 300 pA for a minimal impact on the study object. Scanning electron microscopy was carried out in the Interdisciplinary center for Analytical Microscopy (Kazan Federal University).

4. Conclusions

In conclusion, an extended set of 108 novel quaternary bis-ammonium pyridoxine derivatives carrying various substituents at the quaternary nitrogens and acetal carbon have been synthesized. In the course of primary in vitro screening 13 compounds (5a12, 5c10, 5c12, 5d10, 5f10, 5g10, 5i10, 5l10, 5m8, 5n10, 5o8, 5p8, and 5q8) exhibiting comparable or superior antibacterial activity compared to miramistin, benzalkonium chloride and chlorhexidine were identified (MICs 0.25–4 µg/mL on Gram-positive and 0.5–16 µg/mL on Gram-negative bacteria). A strong correlation between the lipophilicity and antimicrobial activity was found. Most active compounds had logP values in the range of 1–3, while compounds with logP > 6 and logP < 0 were almost inactive. In further investigation of antibacterial and antifungal activity on clinical bacterial and fungal isolates, compounds 5c12, 5i10, 5l10, 5n10, 5o8, 5p8, and 5q8 significantly exceeded miramistin, benzalkonium chloride and chlorhexidine in antibacterial activity. Compounds 5c10, 5c12, 5d10, 5f10, 5n10, and 5p8 exhibited a pronounced antimycotic activity than all reference antiseptics against all fungi tested. All active compounds had comparable values of cytotoxicity with miramistin and chlorhexidine and were less toxic when compared to benzalkonium chloride. In vivo, the leading compound 5c12 was considerably less toxic (LD50 1705 mg/kg) than benzalkonium chloride (LD50 180 mg/kg), miramistine (LD50 1000 mg/kg) and chlorhexidine (LD50 1260 mg/kg) at oral administration on CD-1 mice. Moreover, 5c12 demonstrated comparable or even higher activity than that of the benzalkonium chloride on biofilm-embedded S. aureus, S. epidermidis, E. coli, and P. aeruginosa. A 0.2% aqueous solution of 5c12 showed 97.5% growth inhibition of E. coli CD CF-50 after 5 min of exposure on rat’s skin comparable to reference drugs efficiency. The molecular mechanism of antibacterial activity of 5c12 apparently is the membrane damage since a 5c12 dose-dependent effect on membrane permeability and polarization was observed. The obtained results allow suggesting described quaternary bis-ammonium pyridoxine derivatives as promising lead molecules for the development of the new antiseptics with a broad spectrum of antimicrobial and antifungal activity.

Supplementary Materials

The following are available online at https://www.mdpi.com/1420-3049/25/18/4341/s1, methods of synthesis, analytical characteristics, and copies of 1H and 13C NMR spectra of all new synthesized compounds are described in the Electronic Supplementary Material.

Author Contributions

N.V.S. performed the synthesis of compounds, analyzed results and wrote this paper. M.V.P., S.V.S., M.R.G., R.M.V. and R.S.P. performed the synthesis of compounds and wrote the Supplementary Material. R.R.K., M.N.A. and A.R.K. performed the biological experiments and wrote this paper. D.Y.G. performed the mass-spectra shooting and analysis. A.G.I., E.S.K., E.V.N., S.A.L., M.I.Z. and A.E.S. performed the biological experiments. Y.G.S. conceived and supervised the project, analyzed results, and wrote this paper. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities (project number 0671-2020-0053).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

References

  1. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations; Review on AMR, Wellcome Trust, HM Government: London, UK, 2014; Available online: http://www.jpiamr.eu/wp-content/uploads/2014/12/AMR-Review-Paper-Tackling-a-crisis-for-the-health-and-wealth-of-nations_1-2.pdf (accessed on 20 July 2020).
  2. Frieri, M.; Kumar, K.; Boutin, A. Antibiotic resistance. J. Infect. Public Health. 2017, 10, 369–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. McDonnell, G.; Russell, A.D. Antiseptics and disinfectants: Activity, action, and resistance. Clin. Microbiol. Rev. 1999, 12, 147–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Sheldon, A.T., Jr. Antiseptic “resistance”: Real or perceived threat? Clin. Infect. Dis. 2005, 40, 1650–1656. [Google Scholar] [CrossRef] [PubMed]
  5. Roberts, C.D.; Leaper, D.J.; Assadian, O. The role of topical antiseptic agents within antimicrobial stewardship strategies for prevention and treatment of surgical site and chronic open wound infection. Adv. Wound Care 2017, 6, 63–71. [Google Scholar] [CrossRef] [Green Version]
  6. Gilbert, P.; Moore, L.E. Cationic antiseptics: Diversity of action under a common epithet. J. Appl. Microbiol. 2005, 99, 703–715. [Google Scholar] [CrossRef]
  7. Osmanov, A.; Farooq, Z.; Richardson, M.D.; Denning, D.W. The antiseptic Miramistin: A review of its comparative in vitro and clinical activity. FEMS Microbiol. Rev. 2020, 44, 399–417. [Google Scholar] [CrossRef]
  8. Vijayakumar, R.; Sandle, T. A review on biocide reduced susceptibility due to plasmid-borne antiseptic-resistant genes-special notes on pharmaceutical environmental isolates. J. Appl. Microbiol. 2019, 126, 1011–1022. [Google Scholar] [CrossRef] [Green Version]
  9. Pereira, B.M.P.; Tagkopoulos, I. Benzalkonium chlorides: Uses, regulatory status, and microbial resistance. Appl. Environ. Microbiol. 2019, 85, e00377-19. [Google Scholar]
  10. Kano, S.; Sugibayashi, K. Kinetic analysis on the skin disposition of cytotoxicity as an index of skin irritation produced by cetylpyridinium chloride: Comparison of in vitro data using a three-dimensional cultured human skin model with in vivo results in hairless mice. Pharm. Res. 2006, 23, 329–335. [Google Scholar] [CrossRef]
  11. Jennings, M.C.; Minbiole, K.P.C.; Wuest, W.M. Quaternary ammonium compounds: An antimicrobial mainstay and platform for innovation to address bacterial resistance. ACS Infect. Dis. 2015, 1, 288–303. [Google Scholar] [CrossRef]
  12. Shtyrlin, Y.G.; Petukhov, A.S.; Strelnik, A.D.; Shtyrlin, N.V.; Iksanova, A.G.; Pugachev, M.V.; Pavelyev, R.S.; Dzyurkevich, M.S.; Garipov, M.R.; Balakin, K.V. Chemistry of pyridoxine in drug design. Russ. Chem. Bull. 2019, 68, 911–945. [Google Scholar] [CrossRef]
  13. Shtyrlin, N.V.; Sapozhnikov, S.V.; Koshkin, S.A.; Iksanova, A.G.; Sabirov, A.H.; Kayumov, A.R.; Nureeva, A.A.; Zeldi, M.I.; Shtyrlin, Y.G. Synthesis and antibacterial activity of novel quaternary ammonium pyridoxine derivatives. Med. Chem. 2015, 11, 656–665. [Google Scholar] [CrossRef]
  14. Sapozhnikov, S.V.; Shtyrlin, N.V.; Kayumov, A.R.; Zamaldinova, A.E.; Iksanova, A.G.; Nikitina, E.V.; Krylova, E.S.; Grishaev, D.Y.; Balakin, K.V.; Shtyrlin, Y.G. New quaternary ammonium pyridoxine derivatives: Synthesis and antibacterial activity. Med. Chem. Res. 2017, 26, 3188–3202. [Google Scholar] [CrossRef]
  15. Shtyrlin, N.V.; Sapozhnikov, S.V.; Galiullina, A.S.; Kayumov, A.R.; Bondar, O.V.; Mirchink, E.P.; Isakova, E.B.; Firsov, A.A.; Balakin, K.V. Synthesis and antibacterial activity of quaternary ammonium 4-deoxypyridoxine derivatives. Biomed. Res. Int. 2016, 2016, 3864193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Nikitina, E.V.; Zeldi, M.I.; Pugachev, M.V.; Sapozhnikov, S.V.; Shtyrlin, N.V.; Kuznetsova, S.V.; Evtygin, V.E.; Bogachev, M.I.; Kayumov, A.R.; Shtyrlin, Y.G. Antibacterial effects of quaternary bis-phosphonium and ammonium salts of pyridoxine on Staphylococcus aureus cells: A single base hitting two distinct targets? World J. Microbiol. Biotechnol. 2016, 32, 1–7. [Google Scholar] [CrossRef] [PubMed]
  17. Shtyrlin, Y.G.; Shtyrlin, N.V.; Sapozhnikov, S.V.; Iksanova, A.G.; Kazakova, R.R.; Agafonova, M.N.; Strelnik, A.D. Antiseptic drug. Patent RU No. 2641309, 17 January 2018. [Google Scholar]
  18. Shtyrlin, Y.G.; Shtyrlin, N.V.; Iksanova, A.G.; Nikitina, E.V.; Kazakova, R.R.; Lisovskaya, S.A. Quaternary Ammonium Salt Possessing Antimicrobial and Antibacterial Activity. Patent RU No. 2,666,544 C1, 11 September 2018. [Google Scholar]
  19. Shtyrlin, Y.G.; Shtyrlin, N.V.; Sapozhnikov, S.V.; Pavelyev, R.S. Method of producing 5,8-(bis(methylene(N,N-dimethyl-N-dodecylammonium))-2-ethyl-4H-[1,3]dioxino[4,5-c]pyridinium dichloride. Application RU No. 2,697,848 C1, 21 August 2019. [Google Scholar]
  20. Grigor’ev, A.A.; Shtyrlin, N.V.; Gabbasova, R.R.; Zeldi, M.I.; Grishaev, D.Y.; Gnezdilov, O.I.; Balakin, K.V.; Nasakin, O.E.; Shtyrlin, Y.G. Synthesis, antibacterial and antitumor activity of methylpyridinium salts of pyridoxine functionalized 2-amino-6-sulfanylpyridine-3,5-dicarbonitriles. Synth. Comm. 2018, 48, 2288–2304. [Google Scholar]
  21. Pavelyev, R.S.; Bondar, O.V.; Nguyen, T.N.T.; Ziganshina, A.A.; Al Farroukh, M.; Karwt, R.; Alekbaeva, G.D.; Pugachev, M.V.; Yamaleeva, Z.R.; Kataeva, O.N.; et al. Synthesis and in vitro antitumor activity of novel alkenyl derivatives of pyridoxine, bioisosteric analogs of feruloyl methane. Bioorg. Med. Chem. 2018, 26, 5824–5837. [Google Scholar] [CrossRef]
  22. Csizmadia, F.; Tsantili-Kakoulidou, A.; Panderi, I.; Darvas, F. Prediction of distribution coefficient from structure. 1. Estimation method. J. Pharm. Sci. 1997, 86, 865–871. [Google Scholar] [CrossRef]
  23. United Nations. Globally Harmonized System of Classification and Labeling of Chemicals (GHS), 4th ed.; United Nations: New York, NY, USA; Geneva, Switzerland, 2011; pp. 109–120. [Google Scholar]
  24. Bodor, N. Labile quaternary ammonium salts as soft antimicrobials. J. Med. Chem. 1980, 23, 469–474. [Google Scholar] [CrossRef]
  25. Krivoshein, J.S.; Rud’ko, A.P. Therapeutic Preparation. Patent RU No. 2,161,961, 20 January 2001. [Google Scholar]
  26. Material Safety Data Sheet. Available online: https://pfe-pfizercom-d8-prod.s3.amazonaws.com/products/material_safety_data/PZ00711.pdf (accessed on 1 December 2007).
  27. Agafonova, M.N.; Kazakova, R.R.; Lubina, A.P.; Zeldi, M.I.; Nikitina, E.V.; Balakin, K.V.; Shtyrlin, Y.G. Antibacterial activity profile of miramistin in in vitro and in vivo models. Microb. Pathog. 2020, 142, 104072. [Google Scholar] [CrossRef]
  28. Merianos, J.J. Surface-active agents. In Block’s Disinfection, Sterilization, and Preservation; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2001; pp. 63–320. [Google Scholar]
  29. Kayumov, A.R.; Khakimullina, E.N.; Sharafutdinov, I.S.; Trizna, E.Y.; Latypova, L.Z.; Lien, H.T.; Margulis, A.B.; Bogachev, M.I.; Kurbangalieva, A.R. Inhibition of biofilm formation in Bacillus subtilis by new halogenated furanones. J. Antibiot. 2015, 68, 297–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Trizna, E.Y.; Khakimullina, E.N.; Latypova, L.Z.; Kurbangalieva, A.R.; Sharafutdinov, I.S.; Evtyugin, V.G.; Babynin, E.V.; Bogachev, M.I.; Kayumov, A.R. Thio derivatives of 2(5H)-furanone as inhibitors against bacillus subtilis biofilms. Acta Nat. 2015, 7, 102–107. [Google Scholar] [CrossRef]
  31. Herigstad, B.; Hamilton, M.; Heersink, J. How to optimize the drop plate method for enumerating bacteria. J. Microbiol. Methods 2001, 44, 121–129. [Google Scholar] [CrossRef]
  32. Sharafutdinov, I.S.; Trizna, E.Y.; Baidamshina, D.R.; Ryzhikova, M.N.; Sibgatullina, R.R.; Khabibrakhmanova, A.M.; Latypova, L.Z.; Kurbangalieva, A.R.; Rozhina, E.V.; Klinger-Strobel, M.; et al. Antimicrobial effects of sulfonyl derivative of 2(5H)-furanone against planktonic and biofilm associated methicillin-resistant and -susceptible Staphylococcus aureus. Front. Microbiol. 2017, 8, 2246. [Google Scholar] [CrossRef] [PubMed]
  33. Baidamshina, D.R.; Trizna, E.Y.; Holyavka, M.G.; Bogachev, M.I.; Artyukhov, V.G.; Akhatova, F.S.; Rozhina, E.V.; Fakhrullin, R.F.; Kayumov, A.R. Targeting microbial biofilms using Ficin, a nonspecific plant protease. Sci. Rep. 2017, 7, 46068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Kazakova, R.R.; Luong, D.T. Anesthetics for magnetic resonance studies in rodents (Systematic review of experimental results). Eksp. Klin. Farmakol. 2016, 79, 39–44. [Google Scholar]
  35. Wang, J.; Chou, S.; Xu, L.; Zhu, X.; Dong, N.; Shan, A.; Chen, Z. High specific selectivity and Membrane-Active Mechanism of the synthetic centrosymmetricα-helical peptides with Gly-Gly pairs. Sci. Rep. 2015, 5, 15963. [Google Scholar] [CrossRef] [Green Version]
  36. Zhu, X.; Dong, N.; Wang, Z.; Ma, Z.; Zhang, L.; Ma, Q.; Shan, A. Design of imperfectly amphipathic a-helical antimicrobial peptides with enhanced cell selectivity. Acta Biomater. 2014, 10, 244–257. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds 5a8–5r18 are available from the authors.
Molecules 25 04341 g001 550
Figure 1. The structures of QAC based on pyridoxine derivatives obtained by us earlier [13,14,15,16,17,18,19] and compounds 5a8–5r18 synthesized in this work.
Figure 1. The structures of QAC based on pyridoxine derivatives obtained by us earlier [13,14,15,16,17,18,19] and compounds 5a8–5r18 synthesized in this work.
Molecules 25 04341 g001
Molecules 25 04341 sch001 550
Scheme 1. Reagents and conditions. (i) R1C(O)R2, HCl, 3–5 °C, 3 h; or C6H6, R1C(O)R2, p-TsOH, reflux, 17 h, (ii) H2O, NaOH, 20 °C, (iii) CH2Cl2, SOCl2, 20 °C, 17 h, (iv) H2O/CHCl3, NaHCO3, (v) CHCl3, TCICA, reflux, 4 h, (vi) C2H5OH, R3N(CH3)2, 70 °C, 5 h.
Scheme 1. Reagents and conditions. (i) R1C(O)R2, HCl, 3–5 °C, 3 h; or C6H6, R1C(O)R2, p-TsOH, reflux, 17 h, (ii) H2O, NaOH, 20 °C, (iii) CH2Cl2, SOCl2, 20 °C, 17 h, (iv) H2O/CHCl3, NaHCO3, (v) CHCl3, TCICA, reflux, 4 h, (vi) C2H5OH, R3N(CH3)2, 70 °C, 5 h.
Molecules 25 04341 sch001
Molecules 25 04341 g002 550
Figure 2. Lg1/MIC versus calculated logP relationship for novel bis-ammonium salts of pyridoxine. The parabolic line shows the polynomial approximation by using a second order model. Inactive compounds (MIC > 64 mg/mL) are not shown.
Figure 2. Lg1/MIC versus calculated logP relationship for novel bis-ammonium salts of pyridoxine. The parabolic line shows the polynomial approximation by using a second order model. Inactive compounds (MIC > 64 mg/mL) are not shown.
Molecules 25 04341 g002
Molecules 25 04341 g003 550
Figure 3. The effect of 5c12 and reference antiseptics on biofilm-embedded bacteria. (A)—S. aureus; (B)—S. intermedius; (C)—E. coli, (D)—P. aeruginosa. The 48-h biofilms were treated with 1–16 × MBCs of benzalkonium chloride (circles), miramistin (squares), or 5c12 (triangles) for 24 h and then quantified by CFU counting. Data are present as medians from five independent experiments with interquartile range (M ± IQR). Dotted line shows 3 log-decrease of viable cells.
Figure 3. The effect of 5c12 and reference antiseptics on biofilm-embedded bacteria. (A)—S. aureus; (B)—S. intermedius; (C)—E. coli, (D)—P. aeruginosa. The 48-h biofilms were treated with 1–16 × MBCs of benzalkonium chloride (circles), miramistin (squares), or 5c12 (triangles) for 24 h and then quantified by CFU counting. Data are present as medians from five independent experiments with interquartile range (M ± IQR). Dotted line shows 3 log-decrease of viable cells.
Molecules 25 04341 g003
Molecules 25 04341 g004 550
Figure 4. In vivo antibacterial efficacy test (Mean ± SD) using a rat skin model. log10 number of viable cells in the control and the number of viable cells after exposure with 5c12, miramistin, benzalkonium chloride, and chlorhexidine, n = 6.
Figure 4. In vivo antibacterial efficacy test (Mean ± SD) using a rat skin model. log10 number of viable cells in the control and the number of viable cells after exposure with 5c12, miramistin, benzalkonium chloride, and chlorhexidine, n = 6.
Molecules 25 04341 g004
Molecules 25 04341 g005 550
Figure 5. The effect of 5c12 on the electric potential of the bacterial membrane determined using a membrane-potential-sensitive cyanine dye DiSC3(5) (10 min treatment by 1–8 × MBC (A,B) and 20 min treatment by 1–8 × MBC (C,D)). Asterisks denote a statistically significant difference in comparison with untreated cells. * statistically significant difference from the control.
Figure 5. The effect of 5c12 on the electric potential of the bacterial membrane determined using a membrane-potential-sensitive cyanine dye DiSC3(5) (10 min treatment by 1–8 × MBC (A,B) and 20 min treatment by 1–8 × MBC (C,D)). Asterisks denote a statistically significant difference in comparison with untreated cells. * statistically significant difference from the control.
Molecules 25 04341 g005
Molecules 25 04341 g006 550
Figure 6. Scanning Electron Microscopy microphotographs of S. aureus ATCC209p (A,C) and E. coli CDC F-50 (B,D). Untreated cells (A,B) and bacteria treated by 0.2% solution of 5c12 for 30 min (C,D). 50,000× magnification.
Figure 6. Scanning Electron Microscopy microphotographs of S. aureus ATCC209p (A,C) and E. coli CDC F-50 (B,D). Untreated cells (A,B) and bacteria treated by 0.2% solution of 5c12 for 30 min (C,D). 50,000× magnification.
Molecules 25 04341 g006
Table
Table 1. In vitro antibacterial activity of novel bis-ammonium salts of pyridoxine a.
Table 1. In vitro antibacterial activity of novel bis-ammonium salts of pyridoxine a.
CompoundMICs (µg/mL)LogP
Gram-Positive BacteriaGram-Negative Bacteria
S. aureus ATCC 29213S. epidermidis(clinical)B. subtilis 168E. coli ATCC 25922K. pneumoniae 1813P. aeruginosa ATCC 27853
5a8646464>6464>64–1.74
5a10222322>640.03
5a12428164321.81
5a143264>64>6464>643.59
5a16>64>64>64>64>64>645.37
5a18>64>64>64>64>64>647.15
5b864>64>64>64>64>64–1.51
5b10222322640.26
5b12818164162.04
5b14>64>64>64>64>64>643.82
5b166464646464645.60
5b18>64>64>64>64>64>647.38
5c8323264>6432>64–0.88
5c100.50.53281160.90
5c12124164322.68
5c141616646464644.46
5c16>64>64>64>64>64>646.24
5c18>64>64>64>64>64>648.01
5d81616>64>6416>64–0.43
5d100.250.582181.35
5d1211–22162163.12
5d141616>64>6464644.90
5d16>64>64>64>64>64>646.68
5d16>64>64>64>64>64>648.46
5e8323232>6432>64–0.40
Chlorhexidine2111244.51
Miramistin2224>64642.43
Benzalkonium chloride120.51>6464-
5e1021281161.38
5e1282488323.16
5e14163264>6432>644.94
5e16>64>64>64>64>64>646.72
5e18>64>64>64>64>64>648.49
5f84864648640.01
5f100.250.542141.79
5f12112324323.57
5f143264>64>6464>645.35
5f16>64>64>64>64>64>647.13
5f18>64>64>64>64>64>648.90
5g88168648640.09
5g100.50.5120.581.84
5g121142283.65
5g143232646464>645.43
5g16>64>64>64>64>64>647.21
5g18>64>64>64>64>64>648.99
5h881686416>640.05
5h102114281.83
5h1244488323.60
5h1416>64>64>64>64>645.38
5h16>64>64>64>64>64>647.16
5h18>64>64>64>64>64>648.94
5i8222322320.46
5i100.50.521142.24
5i12128168324.01
5i146464>64>64>64>645.79
5i16>64>64>64>64>64>647.57
5i18>64>64>64>64>64>649.35
5j8444644640.49
5j101112242.27
Chlorhexidine2111244.51
Miramistin2224>64642.43
Benzalkonium chloride120.51>6464-
5j12841688324.05
5j143264>64>64>64>645.83
5j16>64>64>64>64>64>647.60
5j18>64>64>64>64>64>649.38
5k8444644640.49
5k101122242.27
5k128416832324.05
5k143264>64>64>64>645.83
5k16>64>64>64>64>64>647.60
5k18>64>64>64>64>64>649.38
5l811811610.90
5l100.5210.540.52.68
5l1284161616>644.46
5l143232>64>64>64>646.24
5l16>64>64>64>64>64>648.01
5l18>64>64>64>64>64>649.79
5m80.50.5120.5161.35
5m101122483.12
5m1281632>6432>644.90
5m14>64>64>64>64>64>646.68
5m16>64>64>64>64>64>648.46
5m18>64>64>64>64>64>6410.24
5n811181161.38
5n101124243.16
5n12816323232644.94
5n14>64>64>64>64>64>646.72
5n16>64>64>64>64>64>648.49
5n18>64>64>64>64>64>6410.27
5o81122182.24
5o10828164164.01
5o12168643232645.79
Chlorhexidine2111244.51
Miramistin2224>64642.43
Benzalkonium chloride120.51>6464-
5o14>64>64>64>64>64>647.57
5o16>64>64>64>64>64>649.35
5o18>64>64>64>64>64>6411.13
5p82224483.16
5p1088323264>644.94
5p12>64>64>64>64>64>646.72
5p14>64>64>64>64>64>648.49
5p16>64>64>64>64>64>6410.27
5p18>64>64>64>64>64>6412.05
5q820.522182.04
5q102248483.82
5q121632>64>64>64>645.60
5q14>64>64>64>64>64>647.37
5q16>64>64>64>64>64>649.15
5q18>64>64>64>64>64>6410.93
5r81616166416>64–0.01
5r1021121161.77
5r12824164163.55
5r143264>6464>64>645.32
5r16>64>64>64>64>64>647.10
5r18>64>64>64>64>64>648.88
Chlorhexidine2111244.51
Miramistin2224>64642.43
Benzalkonium chloride120.51>6464-
a MICs for the most active compounds are highlighted in bold.
Table
Table 2. In vitro antimicrobial activity of novel bis-ammonium salts of pyridoxine on clinical bacterial isolates.
Table 2. In vitro antimicrobial activity of novel bis-ammonium salts of pyridoxine on clinical bacterial isolates.
StrainsMICs (µg/mL)
5a125c105c125d105f105g105i105l105m85n105o85p85q8ChlorhexidineBenzalkonium ChlorideMiramistin
S. haemolyticus 837 MRSH1664464161684324848643264
S. aureus 967 MRSA1664464161684324848643264
S. aureus 983 MRSA1664464161684324848643264
S. aureus 2521421424121212216
S. intermedius 1143 MRSI22242222221114432
S. aureus 2020 MRSA32>648641616168644848643264
Moraxella sp.76416644648884322424>643264
Moraxella sp.7658644648884322424>643264
Moraxella sp.82916644648884324824>643264
Acinetobacter spp. 132648641616164644888643264
Acinetobacter spp. 332648641616168324848643264
Pseudomonas spp. 516>64464161684644848>643264
Pseudomonas spp. 632644641616164324828>643264
Klebsiella spp. 113264864161684324848>6432>64
Klebsiella spp. 1232>648>641616164644848>643264
Proteus spp. 17>64>6464>64643264>64>64>6464>6464>6464>64
Table
Table 3. In vitro antifungal activity of novel bis-ammonium salts of pyridoxine.
Table 3. In vitro antifungal activity of novel bis-ammonium salts of pyridoxine.
CompoundMinimum Inhibitory Concentrations (MICs) (µg/mL)
Trichophyton rubrum 1336 (clinical)Aspergillus niger F-1119Candida albicans NCTC- 885-653Fusarium oxysporum KM-19 (clinical)
5a1232161632
5c1016848
5c1216848
5d102424
5f101616816
5g1032323232
5i1032161632
5l1032161632
5m8128128128128
5n108448
5o832323232
5p88448
5q864323264
Miramistin32323232
Chlorhexidine12812864128
Benzalkonium chloride168816
Table
Table 4. Cytotoxicity of novel bis-ammonium salts of pyridoxine.
Table 4. Cytotoxicity of novel bis-ammonium salts of pyridoxine.
CompoundCC50, µg/mL (HEK-293)
5a123.11 ± 0.5
5c103.83 ± 0.7
5c123.38 ± 0.8
5d102.81 ± 1.2
5f104.04 ± 0.6
5g103.86 ± 0.8
5i102.22 ± 0.4
5l102.79 ± 0.8
5m83.48 ± 1.2
5n102.02 ± 0.4
5o84.26 ± 0.9
5p83.11 ± 0.8
5q83.69 ± 0.7
Miramistin6.83 ± 1.1
Chlorhexidine5.48 ± 1.5
Benzalkonium chloride1.02 ± 0.4
Table
Table 5. Toxicology data obtained on oral administration of compounds 5c12, 5d10, and 5p8 to CD-1 mice.
Table 5. Toxicology data obtained on oral administration of compounds 5c12, 5d10, and 5p8 to CD-1 mice.
CompoundLD50, mg/kg
5c121705
5d10809
5p8474
Benzalkonium chloride180 [22]
Miramistin1000 [23]
Chlorhexidine1260 [24]
Table
Table 6. Bactericidal activity of compound 5c12, benzalkonium chloride, and miramistin.
Table 6. Bactericidal activity of compound 5c12, benzalkonium chloride, and miramistin.
StrainMBC (µg/mL)
5c12Benzalkonium ChlorideMiramistin
S. aureus ATCC 29213448
S. epidermidis884
P. aeruginosa ATCC 27853128128128
E. coli ATCC 259226428
Table
Table 7. In vivo antibacterial efficacy (Mean ± SD) of 0.2% aqueous solution 5c12, miramistin, benzalkonium chloride and chlorhexidine in a rat skin model, n = 6.
Table 7. In vivo antibacterial efficacy (Mean ± SD) of 0.2% aqueous solution 5c12, miramistin, benzalkonium chloride and chlorhexidine in a rat skin model, n = 6.
CompoundGrowth Inhibition Percentage (CFU/cm2)
5c1297.5 ± 1.7
Miramistin97.2 ± 1.8
Benzalkonium chloride96.8 ± 2.0
Chlorhexidine95.7 ± 3.4

Share and Cite

MDPI and ACS Style

Shtyrlin, N.V.; Pugachev, M.V.; Sapozhnikov, S.V.; Garipov, M.R.; Vafina, R.M.; Grishaev, D.Y.; Pavelyev, R.S.; Kazakova, R.R.; Agafonova, M.N.; Iksanova, A.G.; et al. Novel Bis-Ammonium Salts of Pyridoxine: Synthesis and Antimicrobial Properties. Molecules 2020, 25, 4341. https://doi.org/10.3390/molecules25184341

AMA Style

Shtyrlin NV, Pugachev MV, Sapozhnikov SV, Garipov MR, Vafina RM, Grishaev DY, Pavelyev RS, Kazakova RR, Agafonova MN, Iksanova AG, et al. Novel Bis-Ammonium Salts of Pyridoxine: Synthesis and Antimicrobial Properties. Molecules. 2020; 25(18):4341. https://doi.org/10.3390/molecules25184341

Chicago/Turabian Style

Shtyrlin, Nikita V., Mikhail V. Pugachev, Sergey V. Sapozhnikov, Marsel R. Garipov, Rusalia M. Vafina, Denis Y. Grishaev, Roman S. Pavelyev, Renata R. Kazakova, Mariya N. Agafonova, Alfiya G. Iksanova, and et al. 2020. "Novel Bis-Ammonium Salts of Pyridoxine: Synthesis and Antimicrobial Properties" Molecules 25, no. 18: 4341. https://doi.org/10.3390/molecules25184341

Article Metrics

Back to TopTop